Recent advances in the treatment of hormone receptor positive HER2 negative metastatic breast cancer

被引：26

作者：

Fedele, Palma ^{[1
]}

Orlando, Laura ^{[1
]}

Schiavone, Paola ^{[1
]}

Calvani, Nicola ^{[1
]}

Caliolo, Chiara ^{[1
]}

Quaranta, Annamaria ^{[1
]}

Nacci, Angelo ^{[1
]}

Cinieri, Saverio ^{[1
,2
]}

机构：

[1] A Perrino Hosp, Med Oncol & Breast Unit, I-72100 Brindisi, Italy

[2] European Inst Oncol, Div Med Oncol, Milan, Italy

来源：

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY | 2015年 / 94卷 / 03期

关键词：

Targeted agents; Metastatic breast cancer; Endocrine therapy; Endocrine resistance; Next generation sequencing technologies; RANDOMIZED PHASE-II; EVEROLIMUS PLUS EXEMESTANE; PLACEBO-CONTROLLED TRIAL; POSTMENOPAUSAL WOMEN; ESTROGEN-RECEPTOR; ENDOCRINE THERAPY; DOUBLE-BLIND; PROGESTERONE-RECEPTOR; AROMATASE INHIBITORS; PD; 0332991;

D O I：

10.1016/j.critrevonc.2015.01.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Endocrine therapy is the recommended systemic therapy for hormone receptor (HR) positive metastatic breast cancer (MBC). However so far the limited number of endocrine agents and the onset of endocrine resistance have severely limited the therapeutic options for this patients. In the last years many targeted agents have been investigated to prevent or overcome endocrine resistance; only a few of them have been found effective in HR positive MBC, such as everolimus, CK4/6 inhibitors and HDAC inhibitors. Furthermore, translational medicine studies using next generation sequencing technologies have evaluated genetic variations of a broad panel of cancer-related genes and explored their correlations with targeted agents benefit. In some studies predictive biomarkers have been identified and many ongoing studies are evaluating the efficacy of targeted drugs in HR positive MBC patients selected for biomarkers or stratified by pathways amplification. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：291 / 301

页数：11

共 57 条

[1] An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells [J].

Aesoy, Reidun ;

Sanchez, Betzabe Chavez ;

Norum, Jens Henrik ;

Lewensohn, Rolf ;

Viktorsson, Kristina ;

Linderholm, Barbro .

MOLECULAR CANCER RESEARCH, 2008, 6 (10) :1630-1638

[2]

[Anonymous], ASCO ANN M P

[3]

[Anonymous], ASCO M, DOI DOI 10.1200/JCO.2010.28.15_SUPPL.3060

[4] Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance [J].

Arpino, Grazia ;

Wiechmann, Lisa ;

Osborne, C. Kent ;

Schiff, Rachel .

ENDOCRINE REVIEWS, 2008, 29 (02) :217-233

[5] Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study [J].

Bachelot, Thomas ;

Bourgier, Celine ;

Cropet, Claire ;

Ray-Coquard, Isabelle ;

Ferrero, Jean-Marc ;

Freyer, Gilles ;

Abadie-Lacourtoisie, Sophie ;

Eymard, Jean-Christophe ;

Debled, Marc ;

Spaeth, Dominique ;

Legouffe, Eric ;

Allouache, Djelila ;

El Kouri, Claude ;

Pujade-Lauraine, Eric .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (22) :2718-2724

[6] Estrogen Receptor and Progesterone Receptor As Predictive Biomarkers of Response to Endocrine Therapy: A Prospectively Powered Pathology Study in the Tamoxifen and Exemestane Adjuvant Multinational Trial [J].

Bartlett, John M. S. ;

Brookes, Cassandra L. ;

Robson, Tammy ;

van de Velde, Cornelis J. H. ;

Billingham, Lucinda J. ;

Campbell, Fiona M. ;

Grant, Margaret ;

Hasenburg, Annette ;

Hille, Elysee T. M. ;

Kay, Charlene ;

Kieback, Dirk G. ;

Putter, Hein ;

Markopoulos, Christos ;

Kranenbarg, Elma Meershoek-Klein ;

Mallon, Elizabeth A. ;

Dirix, Luc ;

Seynaeve, Caroline ;

Rea, Daniel .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (12) :1531-1538

[7]

Baselga J, 2011, EUR MULT CANC C EMCC

[8] Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer [J].

Baselga, Jose ;

Campone, Mario ;

Piccart, Martine ;

Burris, Howard A., III ;

Rugo, Hope S. ;

Sahmoud, Tarek ;

Noguchi, Shinzaburo ;

Gnant, Michael ;

Pritchard, Kathleen I. ;

Lebrun, Fabienne ;

Beck, J. Thaddeus ;

Ito, Yoshinori ;

Yardley, Denise ;

Deleu, Ines ;

Perez, Alejandra ;

Bachelot, Thomas ;

Vittori, Luc ;

Xu, Zhiying ;

Mukhopadhyay, Pabak ;

Lebwohl, David ;

Hortobagyi, Gabriel N. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (06) :520-529

[9] Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer [J].

Baselga, Jose ;

Semiglazov, Vladimir ;

van Dam, Peter ;

Manikhas, Alexey ;

Bellet, Meritxell ;

Mayordomo, Jose ;

Campone, Mario ;

Kubista, Ernst ;

Greil, Richard ;

Bianchi, Giulia ;

Steinseifer, Jutta ;

Molloy, Betty ;

Tokaji, Erika ;

Gardner, Humphrey ;

Phillips, Penny ;

Stumm, Michael ;

Lane, Heidi A. ;

Dixon, J. Michael ;

Jonat, Walter ;

Rugo, Hope S. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2630-2637

[10] FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer [J].

Bergh, Jonas ;

Jonsson, Per-Ebbe ;

Lidbrink, Elisabet Kerstin ;

Trudeau, Maureen ;

Eiermann, Wolfgang ;

Brattstrom, Daniel ;

Lindemann, Justin P. O. ;

Wiklund, Fredrik ;

Henriksson, Roger .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) :1919-1925

← 1 2 3 4 5 6 →